Navigation Links
U.S. Food and Drug Administration (FDA) Delays Review of Takeda's Investigational Type 2 Diabetes Therapies, Alogliptin and Alogliptin/Pioglitazone
Date:11/18/2011

ial outlook, which was announced on November 4, 2011, because of this delay.

About Type 2 Diabetes

Type 2 diabetes is the most common form of diabetes and has reached epidemic proportions globally. More than 23 million Americans currently live with type 2 diabetes, and at least seven million are unaware that they have the disease. Type 2 diabetes is a progressive and chronic condition and patients should work with a health care professional to manage and monitor their disease. In addition to diet and exercise, patients often need to take medication in order to help manage glucose control. The global health care expenditures to treat diabetes and prevent its complications were estimated at $376 billion in 2010. By 2030, this number is projected to exceed $490 billion.

About alogliptin and alogliptin/pioglitazone

Alogliptin is a DPP-4i being investigated in the U.S., as an adjunct to diet and exercise, for the treatment of type 2 diabetes. DPP-4 inhibitors address insulin deficiency by slowing the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). As a result, an increased amount of active incretins enables the pancreas to secrete insulin in a glucose dependent manner, thereby assisting in the management of blood glucose levels. An NDA for alogliptin was approved in April 2010 by the Japanese Ministry of Health, Labour and Welfare for the treatment of type 2 diabetes, and the therapy is currently available under the brand name NESINA® in this market.

Alogliptin/pioglitazone is a fixed-dose combination therapy in development for the treatment of type 2 diabetes, which combines alogliptin and pioglitazone in a single tablet. Pioglitazone is a TZD that directly targets insulin resistance, a condition in which the body does not efficiently use the insulin it produces to control blood glucose levels, and is approved in adults for the treatment of type
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
2. Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
3. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
4. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
5. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
6. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
7. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
8. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
9. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
10. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
11. New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... NEW YORK and KING OF PRUSSIA, ... Hemophilia Foundation (NHF) has awarded CSL Behring ... longstanding and unwavering commitment to advancing science and improving the ... by Paul Perreault , CEO and Managing Director, CSL ... New York City on May 21. ...
(Date:5/22/2015)... , May 22, 2015 ... Assay Market by Product (Consumables, Instruments, Services), by Test ... (ELISA, Chromatography, Flow Cytometry), by End Users - Global ... Assays Market is expected to reach $736.85 Million by ... CAGR of 10.25%. Browse 71 market ...
(Date:5/22/2015)... , May 22, 2015 Research and ... the addition of the "Latest Regulations on ... report to their offering. This is ... issued a guidance on international multi-center clinical trials ... which has begun to be implemented on March ...
Breaking Medicine Technology:National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 2National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 4Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 42015 Regulations on Pharmaceutical International Multi-Center Clinical Trials in China 2
(Date:5/22/2015)... Hollywood, CA (PRWEB) May 22, 2015 ... at Sunset Plaza Dental announces that they are ... cosmetic, restorative and other dental treatments. At consultations, ... interest them. Questions regarding what certain treatments can ... also be covered during this initial appointment. If ...
(Date:5/22/2015)... Medivo, Inc., a leader in lab data analytics, ... in ‘Baby Boomers’ Screened for HCV Following the 2012 CDC ... at Digestive Disease Week, May 16-19, 2015. , The ... members Carol Smyth, MB; Jason Bhan, MD; Tatiana Sorokina, MSc; ... Nancy Reau, MD from the University of Chicago, Chicago, IL. ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 A ... at the American Society of Clinical Oncology (ASCO)’s ... improved survival rates for those patients who received ... regimen of pemetrexed/cisplatin. Bevacizumab (Avastin® Genentech, Inc.) is ... and it is already routinely used to treat ...
(Date:5/22/2015)... 22, 2015 DMG Productions announces the ... to broadcast on Friday, May 29, 2015 at 7:30 ... , In this episode Innovations will explore Interstate Restoration, ... business quickly through disaster recovery and restoration. , Additionally, ... works collaboratively to develop and deliver training and education ...
(Date:5/22/2015)... Phoenix, AZ (PRWEB) May 22, 2015 ... Special Olympics, Parker and Sons is offering to donate ... for installing an AC unit or water softening system. ... their behalf; Parker and Sons gets business; and the ... , The Special Olympics helps over 4.4 million ...
Breaking Medicine News(10 mins):Health News:West Hollywood Dental Office, Sunset Plaza Dental is Now Offering Complimentary Consultations 2Health News:Medivo Study Finds HCV Positivity Rates are 250% Higher Among Baby Boomers 2Health News:Mesothelioma Research Organization Excited About Imminent Improvement to Standard of Care 2Health News:New Episode of Innovations Airing Friday, May 29, 2015 Via Discovery Channel 2Health News:Parker and Sons is Proud to Support the Special Olympics with Their Everybody Wins Program 2
... it is not. Yet its,success is none-the-less impressive. ... both worldwide and in the,U.S. since the turn ... for virtual,reality in surgery, medical education, therapy and ... Virtual Reality Market in the US Healthcare,Sector: Markets ...
... Oct. 19 How far can a bright, ... for one super smile could take YOU,all the ... at the People,s,Choice Awards. Listen to this ... journalists can access video, audio, text, graphics and,photos ...
... to fumes at home less likely to pass exams, research ... is secondhand smoke a threat to teen health, it can ... , Researchers at Temple University found that 16- and 18-year-olds ... likely to pass standardized tests than their peers. , They ...
... With safety issues making,headlines, pharmaceutical and ... Organizations are relying on their quality function,to ... Proper,staffing of quality roles is just one ... study by pharmaceutical benchmarking leader Best,Practices, LLC ...
... Single-Payer ... Healthcare, ... thanks Al Gore for,his forceful new words in support of the ... and that is,succeeding in nearly every other industrialized democracy. The ...
... MENTOR, Ohio, Oct. 19 STERIS Corporation,(NYSE: ... its fiscal 2008 second,quarter earnings release before the ... conference call at 10:00 a.m. Eastern time. The ... at http://www.steris-ir.com or via phone,by dialing ...
Cached Medicine News:Health News:Virtual Reality Technology Finds Ready and Willing Market in Healthcare 2Health News:Secondhand Smoke Hurts Kids' Grades 2Health News:Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance 2Health News:National Nurses Movement Lauds Al Gore for Leadership on Single-Payer Healthcare 2Health News:STERIS Corporation Announces Date of Fiscal 2008 Second Quarter Earnings Release and Conference Call 2Health News:STERIS Corporation Announces Date of Fiscal 2008 Second Quarter Earnings Release and Conference Call 3
...
To enter, dissect, elevate and smooth the flap. Combined features of Spatula, Dissector and Forceps. - Also available in Titanium...
The CGAL gonioscopic contact glass was designed by Roussel and Fankhauser for,laser treatments of the chamber angle. It reduces the laser spot by a factor of 1.5 as compared to a Goldmann Glass....
For newly born children 10 mm internal diameter of the cornea part. Designed to work with argon/YAG Lasers....
Medicine Products: